Menu
Menu
🌍 We’re proud to highlight that Tyrolpath, the largest private pathology lab in western Austria, is the first lab in Austria to adopt MSK-IMPACT®-Flex powered with SOPHiA DDM™, marking a major milestone for precision oncology in the country. With approximately 45,000 new cancer diagnoses reported each year, there is a strong need for comprehensive genomic […]
We’re excited to celebrate Genos Médica, a leader in genetic and genomic medicine in Mexico, as they expand their collaboration with SOPHiA GENETICS to further their research using the SOPHiA DDM™ Platform. Genos Médica is adopting SOPHiA DDM™ Exhanced Whole Exome and Liquid Biopsy applications to strengthen its research capabilities in rare disease and oncology, empowering […]
We’re thrilled to welcome Seguros SURA Colombia to the SOPHiA GENETICS community as they adopt MSK-ACCESS® powered by SOPHiA DDM™ to advance their precision oncology research initiatives. As one of Latin America’s leading healthcare organizations, Seguros SURA Colombia is recognized for its commitment to driving innovation and research that strengthens the healthcare ecosystem. By implementing this cutting-edge liquid biopsy solution for research purposes, […]
BOSTON, United States and ROLLE, Switzerland, November 4, 2025 — SOPHiA GENETICS (Nasdaq: SOPH), a global leader in AI-driven precision medicine, today reported financial results for the third quarter ended September 30, 2025. Third Quarter 2025 Financial Results 2025 Financial Outlook "Q3 was an excellent quarter for SOPHiA GENETICS, with revenue growth accelerating for a third […]
BOSTON, MA, November 11, 2025 – Complete Genomics, a leading innovator in genomic sequencing, today announced a collaboration with SOPHiA GENETICS (NASDAQ: SOPH), a global leader in AI-driven precision medicine, to launch and co-market MSK-ACCESS® and MSK-IMPACT® powered with SOPHiA DDM™ on Complete Genomics’ DNBSEQ-T1+ sequencing platform. The companies aim to broaden access to precision […]
Boston, MA and San Diego, CA, November 11, 2025 – SOPHiA GENETICS (NASDAQ: SOPH), a global leader in AI-driven precision medicine, and Element Biosciences, Inc., a biology company transforming the pace and accessibility of scientific discovery, today announced at the Association for Molecular Pathology (AMP) Annual Meeting a partnership that unites sequencing and AI analytics […]
We are thrilled to share that TomaLab, one of the largest genetic laboratories in Italy, has expanded their partnership with SOPHiA GENETICS, adding exome, solid tumor and hereditary cancer applications to gain insights across multiple cancers and inherited disorders. By combining TomaLab’s deep expertise with our platform’s advanced analytics, they are now poised to deliver […]
BOSTON, United States and ROLLE, Switzerland, October 21, 2025 — SOPHiA GENETICS (Nasdaq: SOPH), a global leader in AI-driven precision medicine, today announced it will release its financial results for the third quarter 2025 before U.S. markets open on Tuesday, November 4, 2025. On that day, SOPHiA GENETICS will host a conference call to discuss its […]
SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures unless specified otherwise.
SOPHiA DDM™ Dx Hereditary Cancer Solution, SOPHiA DDM™ Dx RNAtarget Oncology Solution and SOPHiA DDM™ Dx Homologous Recombination Deficiency Solution are available as CE-IVD products for In Vitro Diagnostic Use in the European Economic Area (EEA), the United Kingdom and Switzerland. SOPHiA DDM™ Dx Myeloid Solution and SOPHiA DDM™ Dx Solid Tumor Solution are available as CE-IVD products for In Vitro Diagnostic Use in the EEA, the United Kingdom, Switzerland, and Israel. Information about products that may or may not be available in different countries and if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact us to obtain the appropriate product information for your country of residence.
All third-party trademarks listed by SOPHiA GENETICS remain the property of their respective owners. Unless specifically identified as such, SOPHiA GENETICS’ use of third-party trademarks does not indicate any relationship, sponsorship, or endorsement between SOPHiA GENETICS and the owners of these trademarks. Any references by SOPHiA GENETICS to third-party trademarks is to identify the corresponding third-party goods and/or services and shall be considered nominative fair use under the trademark law.
